Zollinger-Ellison syndrome: case report and topic review

Authors

  • Rosaura J. Serrano Department of Gastrointestinal Surgery, Instituto Mexicano del Seguro Social, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Mexico City, Mexico
  • Kevin Avilés Department of Gastrointestinal Surgery, Instituto Mexicano del Seguro Social, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Mexico City, Mexico
  • Yanetzy E. Corona Department of Gastrointestinal Surgery, Instituto Mexicano del Seguro Social, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Mexico City, Mexico
  • Gaby A. Alarcón Department of Gastrointestinal Surgery, Instituto Mexicano del Seguro Social, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Mexico City, Mexico

DOI:

https://doi.org/10.18203/2320-6012.ijrms20240856

Keywords:

Gastrinoma, Zollinger-Ellison, Somatostatin receptor scintigraphy

Abstract

Zollinger-Ellison syndrome (ZES) is characterized by gastrin-secreting neuroendocrine tumors (gastrinomas) in the duodenum or pancreas. It is a rare condition, most patients are diagnosed between the ages of 20 and 50, and a higher incidence in men. Gastrinomas are associated with a high risk of malignancy and the diagnosis is confirmed by the secretin stimulation test and imaging studies such as octreotide scintigraphy. We present the case of a 24-year-old man who presented with melena, asthenia, adynamia and abdominal pain, in addition to a history of peptic ulcer. Laboratory tests revealed low levels of hemoglobin and elevated levels of gastrin. Endoscopy showed a giant ulcer and subsequent surgery revealed stomach-jejunum adhesions, gastric lesions and Meckel's diverticulum. Imaging studies confirmed neuroendocrine tumor activity in the pancreas. ZES leads to sustained hypergastrinemia, causing peptic ulcers and other digestive tract complications. Gastrinomas can arise from a variety of locations and can cause peptic ulcers, malabsorption, and diarrhea. Diagnosis requires elevated fasting serum gastrin levels and hypersecretion of gastric acid. Treatment involves discontinuation of proton pump inhibitors (PPIs) before diagnostic testing and surgical resection of tumors in suitable candidates. The diagnosis of ZES can be complicated due to the unreliability of the assays and the need for secretin testing. Surgical resection is recommended for sporadic gastrinomas without metastasis, while medical treatment may be necessary for postsurgical residual hyperacidity. Patients should undergo imaging studies for tumor localization and regular monitoring for complications and recurrences.

Metrics

Metrics Loading ...

References

Metz DC, Cadiot G, Poitras P, Ito T, Jensen RT. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol. 2017;4(4):167-85.

Leung J, Ehrlich A, Fedorowicz Z. Gastrinoma. DynaMed. 2021.

Roses RE, Dempsey DT. Chapter 26: Stomach. Brunicardi F, Andersen DK, Billiar TR, Dunn DL, Kao LS, Hunter JG, et al, Editors. Schwartz's Principles of Surgery. 11th edition. McGraw Hill. 2020.

Chatzipanagiotou O, Schizas D, Vailas M, Tsoli M, Sakarellos P, Sotiropoulou M, et al. All you need to know about gastrinoma today Gastrinoma and Zollinger-Ellison syndrome: A thorough update. J Neuroendocrinol. 2023;35(4):e13267.

Nagtegaal ID, Odze RD, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020;76(2):182-8.

Nicolás, Ortiz V, Shepherd MA, Ponce J. Zollinger-Ellison syndrome. Gastroenterol Hepatol. 1999;22(2):100-112.

Quatrini M, Castoldi L, Rossi G, Cesana BM, Peracchi M, Bardella MT. A follow-up study of patients with Zollinger-Ellison syndrome in the period 1966-2002: Effects of surgical and medical treatments on long-term survival. J Clin Gastroenterol. 2005;39:376-80.

Rossi RE, Elvevi A, Citterio D, Coppa J, Invernizzi P, Mazzaferro V, et al. Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World J Gastroenterol. 2021;27(35):5890-907.

Shao QQ, Zhao BB, Dong LB, Cao HT, Wang WB. Surgical management of Zollinger-Ellison syndrome: Classical considerations and current controversies. World J Gastroenterol. 2019;25(32):4673-81.

Morrow EH, Norton JA. Surgical management of Zollinger-Ellison syndrome; state of the art. Surg Clin North Am. 2009;89(5):1091-103.

Pisegna JR, Norton JA, Slimak GG, Metz DC, Maton PN, Gardner JD, et al. Effects of curative gastrinoma resection on gastric secretory function and antisecretory drug requirement in the Zollinger-Ellison syndrome. Gastroenterology. 1992;102(3):767-78.

McArthur KE, Richardson CT, Barnett CC, Eshaghi N, Smerud MJ, McClelland RN, et al. Laparotomy and proximal gastric vagotomy in Zollinger-Ellison syndrome: results of a 16-year prospective study. Am J Gastroenterol. 1996;91(6):1104-11.

Downloads

Published

2024-03-29

How to Cite

Serrano, R. J., Avilés, K., Corona, Y. E., & Alarcón, G. A. (2024). Zollinger-Ellison syndrome: case report and topic review. International Journal of Research in Medical Sciences, 12(4), 1279–1282. https://doi.org/10.18203/2320-6012.ijrms20240856

Issue

Section

Case Reports